3',5'-O-di(tert-butyldimethylsilyl)-2'-deoxy-2'-fluoroadenosine | 1445390-92-0

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 3',5'-O-di(tert-butyldimethylsilyl)-2'-deoxy-2'-fluoroadenosine
• 英文别名: 3′,5′-O-bis(tert-butyldimethylsilyl)-2′-deoxy-2′-fluoroadenosine；9-[(2R,3R,4R,5R)-4-{[tert-butyl(dimethyl)silyl]oxy}-5-({[tert-butyl(dimethyl)silyl]oxy}methyl)-3-fluorotetrahydrofuran-2-yl]-9H-purin-6-amine；3',5'-di-O-tert-butyldimethylsilyl-2'-deoxy-2'-fluoroadenosine；9-((2R,3R,4R,5R)-4-((tert-Butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)-3-fluorotetrahydrofuran-2-yl)-9H-purin-6-amine；9-[(2R,3R,4R,5R)-4-[tert-butyl(dimethyl)silyl]oxy-5-[[tert-butyl(dimethyl)silyl]oxymethyl]-3-fluorooxolan-2-yl]purin-6-amine
• CAS: 1445390-92-0
• 化学式: C₂₂H₄₀FN₅O₃Si₂
• 分子量: 497.761
• InChiKey: GYZBEHWYBXJHJX-MXHNKVEKSA-N

物化性质

• 沸点：
  536.2±60.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.06
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  97.3
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  3',5'-O-di(tert-butyldimethylsilyl)-2'-deoxy-2'-fluoroadenosine 在 吡啶 、 咪唑 、 氯化亚砜 、 硼氘化钠 、 2,2,6,6-四甲基哌啶氧化物 、 氘代甲醇-d 、 碘苯二乙酸 、 水 、 重水 、 三氟乙酸 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 48.0h， 生成
  参考文献：
  名称：

  [EN] S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS
  [FR] POLYMÈRES OLIGONUCLÉOTIDIQUES INHIBANT LE TRANSPORT DE L'ANTIGÈNE S ET MÉTHODES

  摘要：

  各种实施方式提供了STOPS™聚合物，这些聚合物是S-抗原转运抑制寡核苷酸聚合物，提供了制备它们的方法以及使用它们治疗疾病和症状的方法。在某些实施方式中，STOPS™修饰的寡核苷酸包括至少部分磷硫酸酯化的交替A和C单元序列，具有如本文所述的修饰。通过HBsAg分泌测定确定的STOPS™修饰的寡核苷酸对乙型肝炎的序列无关抗病毒活性，其EC50小于100 nM。

  公开号：

  WO2021119325A1
• 作为产物：
  描述：

  阿糖腺苷 在 吡啶 、 二乙胺基三氟化硫 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 生成 3',5'-O-di(tert-butyldimethylsilyl)-2'-deoxy-2'-fluoroadenosine
  参考文献：
  名称：

  Reaction intermediate analogues as bisubstrate inhibitors of pantothenate synthetase

  摘要：

  The biosynthesis of pantothenate, the core of coenzyme A (CoA), has been considered an attractive target for the development of antimicrobial agents since this pathway is essential in prokaryotes, but absent in mammals. Pantothenate synthetase, encoded by the gene panC, catalyzes the final condensation of pantoic acid with beta-alanine to afford pantothenate via an intermediate pantoyl adenylate. We describe the synthesis and biochemical characterization of five PanC inhibitors that mimic the intermediate pantoyl adenylate. These inhibitors are competitive inhibitors with respect to pantoic acid and possess submicromolar to micromolar inhibition constants. The observed SAR is rationalized through molecular docking studies based on the reported co-crystal structure of 1a with PanC. Finally, whole cell activity is assessed against wild-type Mtb as well as a PanC knockdown strain where PanC is depleted to less than 5% of wild-type levels. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.01.017

文献信息

• SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
  申请人：Alios BioPharma, Inc.

  公开号：US20150105341A1

  公开（公告）日：2015-04-16

  Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, nucleotides and nucleotide analogs.

  本文披露了核苷、核苷酸和核苷酸类似物，以及它们的合成方法以及利用一个或多个核苷、核苷酸和核苷酸类似物治疗如小核糖核病毒和/或黄病毒科感染等疾病和/或症状的方法。
• [EN] CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS<br/>[FR] DINUCLÉOTIDES CYCLIQUES UTILISÉS EN TANT QU'AGENTS ANTICANCÉREUX
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2019074887A1

  公开（公告）日：2019-04-18

  The present invention is directed to compounds of the formula (I), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

  本发明涉及式(I)的化合物，其中所有取代基在此定义，以及包括本发明化合物的药学上可接受的组合物，以及使用这些组合物治疗各种疾病的方法。
• [EN] SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF<br/>[FR] NUCLÉOSIDES SUBSTITUÉS, NUCLÉOTIDES ET ANALOGUES DE CEUX-CI
  申请人：ALIOS BIOPHARMA INC

  公开号：WO2014209983A1

  公开（公告）日：2014-12-31

  Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection, with a nucleoside, a nucleotide and an analog thereof.

  本文披露了核苷、核苷酸及其类似物，包括一个或多个核苷、核苷酸及其类似物的药物组合物，以及合成它们的方法。本文还披露了使用核苷、核苷酸及其类似物来改善和/或治疗副粘病毒感染的方法。
• WO2019180683A5
  申请人：——

  公开号：WO2019180683A5

  公开（公告）日：2022-03-29
• Targeting <i>Mycobacterium tuberculosis</i> Biotin Protein Ligase (MtBPL) with Nucleoside-Based Bisubstrate Adenylation Inhibitors
  作者：Matthew R. Bockman、Alvin S. Kalinda、Riccardo Petrelli、Teresa De la Mora-Rey、Divya Tiwari、Feng Liu、Surendra Dawadi、Madhumitha Nandakumar、Kyu Y. Rhee、Dirk Schnappinger、Barry C. Finzel、Courtney C. Aldrich

  DOI：10.1021/acs.jmedchem.5b00719

  日期：2015.9.24

  Mycobacterium tuberculosis (Mtb), responsible for second leading cause of mortality among infectious diseases worldwide. Mycobacterial biotin protein ligase (MtBPL) is an both latent and symptomatic tuberculosis (TB), remains the essential enzyme in Mtb and regulates lipid metabolism through the post-translational biotinylation of acyl coenzyme A carboxylases. We report the synthesis and evaluation of a systematic series of potent nucleoside-based inhibitors of MtBPL that contain modifications to the ribofuranosyl ring of the nucleoside. All compounds were characterized by isothermal titration calorimetry (ITC) and shown to bind potently with K(D)s <= 2 nM. Additionally, we obtained high-resolution cocrystal structures for a majority of the compounds. Despite fairly uniform biochemical potency, the whole-cell Mtb activity varied greatly with minimum inhibitory concentrations (MIC) ranging from 0.78 to >100 mu M. Cellular accumulation studies showed a nearly 10-fold enhancement in accumulation of a C-2'-alpha analogue over the corresponding C-2'-beta analogue, consistent with their differential whole-cell activity.